Biofrontera ( (DE:B8FK) ) just unveiled an update.
Biofrontera AG announced that by the end of 2024, it had largely met its financial forecasts with revenues of kEUR 21,666 and liquidity of kEUR 3,124, although its EBITDA was slightly below expectations. For 2025, the company anticipates positive EBITDA, steady revenue growth in Europe, and stable revenues from its US licensing business, while planning to maintain liquidity between kEUR 500 and kEUR 1,500 by the end of the year.
More about Biofrontera
Biofrontera AG is a company based in Leverkusen, Germany, operating in the pharmaceutical industry. It is listed on several regulated and unofficial markets in Germany, including Düsseldorf, Frankfurt, Munich, Stuttgart, and Berlin.
Technical Sentiment Signal: Buy
Current Market Cap: €14.95M
See more data about B8FK stock on TipRanks’ Stock Analysis page.